
Compare testosterone gels, injections and other routes by delivery, practical trade-offs, fertility concerns and clinical monitoring needs.

Skin-applied testosterone and testosterone delivered by injection or other routes differ in administration and duration, which affects how clinicians weigh practical demands against monitoring and safety needs.
This article is for informational purposes only and is not medical advice. Personal decisions about testosterone treatment require assessment by a qualified clinician.
Testosterone gels and patches deliver the hormone through the skin. This is called transdermal delivery. The European Association of Urology (EAU) guideline describes both as daily treatment options, with different practical drawbacks despite their shared route.
The EAU describes testosterone gel as providing delivery over roughly 24 hours after daily application. Its practical demands include regular application and the possibility of transferring testosterone to another person through close skin contact.
The guideline identifies covering the application site or selecting a less-contact-prone site as ways to reduce transfer risk. These precautions are part of product counseling, not evidence that transfer becomes impossible.
Gel also creates a specific laboratory issue. The EAU warns that testosterone remaining on the skin at a blood-draw site can contaminate the sample and produce a falsely high result. This makes the application history relevant to interpreting an unexpected laboratory value.
The EAU table describes patches as providing steady testosterone levels. It lists daily application and skin irritation as disadvantages.
That comparison is narrower than saying patches are better or worse than gels. Both involve a daily skin-based treatment, but the practical concern highlighted for patches is irritation. For gel, close-contact transfer and blood-sample contamination also matter.
The clinical distinction is therefore not simply whether treatment avoids a needle. It includes what daily use requires and which route-specific issues need attention during follow-up.
Injections and other non-skin delivery methods introduce different administration demands. The EAU describes options ranging from repeated daily administration to long-lasting treatment, so these routes should not be treated as one uniform alternative to gels.
The guideline lists testosterone enanthate and cypionate among injectable options given at intervals of weeks. Repeated injections and fluctuations in testosterone levels are identified as disadvantages.
The EAU also notes that older injection formulations may produce wide fluctuations that some patients find unpleasant. That observation does not establish that every person experiences the same pattern or symptoms.
The practical trade-off is clear: an injection schedule differs from daily skin application, but less frequent administration does not necessarily mean steadier exposure. The preparation used remains important to both the treatment discussion and the interpretation of blood tests.
The EAU describes testosterone undecanoate injections as allowing longer intervals between administrations and providing relatively stable levels. Their long duration brings a separate concern: treatment cannot be rapidly withdrawn if an adverse effect occurs.
This places convenience and reversibility on different sides of the comparison. A longer interval may reduce the frequency of administration, while also limiting how quickly treatment can be stopped. Clinicians therefore weigh duration as a medical characteristic rather than as a convenience feature alone.
According to the EAU, some oral testosterone undecanoate formulations have absorption affected by dietary fat and require administration with meals. The guideline describes improved oral availability with newer formulations, alongside reports of increased blood pressure.
Avoiding skin application or injections does not remove the need for monitoring. Oral administration changes the practical demands and the safety issues that enter the discussion. It does not make testosterone therapy a treatment that can be judged by convenience alone.
The EAU describes several additional routes:
These descriptions help clarify what using a formulation involves. Repeated administration and an invasive procedure are different burdens, even when both approaches deliver testosterone. Neither characteristic by itself establishes better symptom relief or a better overall safety profile.
All these formulations supply testosterone from outside the body. Changing the delivery route does not remove the broader hormonal effects of that treatment.
The EAU states that exogenous testosterone suppresses gonadotropin secretion and sperm production. It says testosterone therapy is contraindicated for men who desire fertility. Fertility goals therefore belong in treatment planning before the choice narrows to gel versus injection or another route.
This is not a minor preference about administration. Switching from an injection to a skin preparation is not a way to dismiss the fertility concern associated with exogenous testosterone.
The EAU explicitly states that direct comparisons among testosterone products are lacking. Practical differences are well described, but they do not support a universal ranking of formulations.
The guideline reports that raised hematocrit is more frequent with parenteral preparations than with topical preparations. It cites a registry comparison in which long-acting injectable testosterone undecanoate was associated with more hematocrit readings above 50% than gel therapy. This was not a randomized comparison of every product, so it does not establish that every injection has greater hematocrit effects than every topical option.
The EAU also recommends considering gel rather than long-acting depot treatment when initiating therapy in high-risk men, but grades that recommendation as weak. That qualification limits its scope: it is guidance for a particular clinical setting rather than proof that gel is the safest starting option for everyone.
For intranasal testosterone, the guideline describes preliminary findings suggesting less gonadotropin suppression and lower hematocrit risk. Those findings do not establish a fertility-preserving exception or remove the need for safety assessment.
The useful conclusion is specific rather than vague: compare documented administration characteristics and monitoring needs without turning limited comparative findings into a product league table.
The EAU recommends discussing each option’s risks and benefits. It advises basing the choice on the clinical situation and availability, alongside the patient’s needs and expectations.
A useful starting distinction is between understanding possible low testosterone symptoms and comparing ways to deliver prescribed treatment. A preferred route does not answer the separate question of what is causing a person’s symptoms.
The EAU advises interpreting testosterone testing in relation to the formulation used. For gel, it recommends sampling about two to four hours after application and warns about contamination at the blood-draw site.
These are clinician-led sampling considerations, not a universal testing schedule for every product. An isolated result needs the preparation and sampling time attached to it before it can be meaningfully assessed.
Testostra’s explanation of the context behind hormone testing provides background for understanding these discussions. In formulation comparisons, the key point is that the laboratory number and the delivery method cannot be interpreted separately.
The EAU recommends reviewing symptoms and measuring testosterone and hematocrit at baseline and during follow-up. Its monitoring table includes checks at three, six, and twelve months in the first year and annually thereafter.
The guideline describes raised hematocrit as the most common adverse effect of testosterone therapy. It specifies that hematocrit above 54% requires clinician-directed treatment adjustment or withdrawal. This is a clinical action point, not a stand-alone boundary between safe and unsafe treatment.
Blood pressure is also included in the EAU monitoring table at baseline and three months, followed by twelve months and annually. The guideline advises cardiovascular risk assessment before treatment and closer monitoring for men with existing cardiovascular disease or other relevant risk factors. Prostate-related assessment is included as appropriate.
This broader review matters because treatment response and treatment safety are different questions. A testosterone result alone does not replace either symptom review or the other monitoring the guideline describes.
The evidence supports a discussion organized around practical questions rather than a request for the “best” formulation:
These questions keep the comparison connected to clinical care. They also help separate an established delivery characteristic from a broader marketing claim about superiority.
Skin-applied and other testosterone formulations are best viewed as different delivery approaches whose practical demands must be considered together with hormonal effects and clinical monitoring.
Daily application, injection intervals and safety follow-up belong in the prescribing clinician’s discussion; Testostra makes the research behind those trade-offs easier to follow. For men questioning whether symptoms reflect low testosterone or another cause, its coverage separates clinical evidence from treatment claims without assigning a diagnosis or recommending a personal treatment plan.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra